drugset / Trial / NCT01717404

Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)

NCT01717404

Phase 1 Completed 1 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

To understand if Mexiletine will restores normal colonic motility in a patient with irritable bowel syndrome - constipation (IBS-C) and a genetic mutation in SCN5A.

Timeline

Start
2012-10
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Mexiletine Small molecule 400 mg Oral